Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases.

Cancer science - 1 Feb 2022

Chai Rui-Chao, Liu Xing, Pang Bo, Liu Yu-Qing, Li Jing-Jun, Li Yang-Fang, Zhao Zheng, Du Jiang, Bao Zhao Shi, Jiang Tao

Abstract excerpt

Identifying molecular features is an essential component of the management and targeted therapy of brain metastases (BMs). The molecular features are different between primary lung cancers and BMs of lung cancer. Here we report the DNA and RNA mutational profiles of 43 pathological samples of BMs. In addition to previously reported mutational events associated with targeted therapy, PTPRZ1-MET, which was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Brain Neoplasms
Share to Exons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Oncogene Proteins, Fusion

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 34812554
DOI: 10.1111/cas.15211
PMCID: PMC8819346

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases.PMID 34812554Read ↗

Genes associated with increased brain metastasis risk in non–small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non–small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036)Semantic proximity Read ↗

Extensive MET alterations confer clinical response to MET inhibitors in gliomasSemantic proximity Read ↗

Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.Semantic proximity Read ↗

The Mutation Patterns of MET Gene in Lung Cancer and Brain Tumors: Clinical and Therapeutic Implications.Semantic proximity Read ↗

MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype.Semantic proximity Read ↗

Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas.Semantic proximity Read ↗

Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.Semantic proximity Read ↗

Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases.Semantic proximity Read ↗

Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.Semantic proximity Read ↗

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable <i>MET</i> Gene MutationsSemantic proximity Read ↗

Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.Semantic proximity Read ↗

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.